The Alfred Research Alliance leads the world in research excellence and is widely recognised as one of Australia’s leading centres for research excellence and real-world health innovation.
High quality, translational research is a feature of AMREP. Here, clinicians, scientists and students take new discoveries from knowledge creation in fundamental research, right through into clinical practice.
Through our six member organisations, we have a range of research strengths, including:
- Blood diseases and cancer
- Cardiovascular disease
- Diabetes and obesity
- Epidemiology and public health
- Infection and immunity
- Mental health and neuroscience
- Nursing and allied health
- Trauma, critical care and perioperative medicine
Within these categories, our researchers excel in a wide range of areas from metabolomics, bioinformatics, cancer and immunotherapy, to ophthalmology, psychology, respiratory medicine, preventive medicine, rehabilitation and health services research.
These overlapping strengths and interests, together with the strong translational research focus, clinical connections and collaborative environment within the Alliance, optimises learning and strengthens research.
The strength of our research is underpinned by the ability of our members to consistently attract and retain vital funding. In 2017, external research funding won by Alliance members was in excess of $107 million, and some $20 milllion from philanthropy and fundraising revenue.
So what sets the Alliance apart? A number of factors.
Firstly, our co-location with The Alfred, one of Australia’s busiest hospitals, provides a clinically diverse setting that supports patient-centred research while our public health research and unsurpassed collection of clinical registries means we can follow the impact of specific interventions on health outcomes, at both clinical and community levels, over time.
Our health services research improves the delivery of a range of services, ensuring better outcomes for patients, while our extensive capacity for clinical trials (phase I-IV) form a fundamental part of the translational activities here at The Alfred precinct, giving us the depth and breadth of expertise to translate our discoveries into new interventions on-site.
Start-ups and SMEs co-located on site further extend our on-site expertise into biomedical commercialisation
It’s a complete, translational research loop, all on one busy and exciting site in the heart of Melbourne… and that helps make us unique in the biomedical research space.